Announcements Trials
Browse Landscape

Phase

Phase 1/2 3Phase 2 2Phase 3 1Phase 1 1

Status

Recruiting 2Completed 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 3

Conditions

Carcinoma, Non-Small-Cell Lung 48Prostatic Neoplasms 33Breast Neoplasms 23Stomach Neoplasms 16Squamous Cell Carcinoma of Head and Neck 15Lung Neoplasms 15Esophageal Neoplasms 13Neoplasm Metastasis 11Sarcoma 9Neoplasms 9Colorectal Neoplasms 7Urinary Bladder Neoplasms 6Ovarian Neoplasms 6Head and Neck Neoplasms 6Carcinoma, Transitional Cell 6Carcinoma, Renal Cell 6Melanoma 5Uterine Cervical Neoplasms 4Triple Negative Breast Neoplasms 4Small Cell Lung Carcinoma 4Carcinoma, Ovarian Epithelial 4Breast Neoplasms, Male 4Salivary Gland Neoplasms 3Prostatic Neoplasms, Castration-Resistant 3Pancreatic Neoplasms 3Non-Muscle Invasive Bladder Neoplasms 3Leiomyosarcoma 3Inflammatory Breast Neoplasms 3Endometrial Neoplasms 3Carcinoma, Squamous Cell 3

Interventions

enzalutamide 5Docetaxel 3zimberelimab 1sacituzumab govitecan 1quemliclustat 1olaparib 1gedatolisib 1fludrocortisone acetate 1darolutamide 1cabazitaxel 1abiraterone 1Prednisone 1Dexamethasone 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1/2 × Prostatic Neoplasms, Castration-Resistant × Docetaxel × Clear all
NCT06353386 2026-05-26

MK-5684-01A

Merck Sharp & Dohme LLC

Phase 1/2 Recruiting
220 enrolled
Genitourinary

Prostatic Neoplasms, Castration-Resistant

NCT06863272 2026-05-15

IDeate-Prostate02

Merck Sharp & Dohme LLC

Phase 1/2 Recruiting
360 enrolled
Genitourinary

Neoplasm Metastasis, Prostatic Neoplasms, Castration-Resistant

NCT04381832 2025-07-22

Adenosine Receptor Antagonist Combination Therapy for Metastatic Castrate Resistant Prostate Cancer

Arcus Biosciences, Inc.

Phase 1/2 Completed
173 enrolled
Genitourinary

Prostatic Neoplasms, Castration-Resistant

Data powered by HemOnc (CC BY 4.0) Colophon âš¡